Last reviewed · How we verify
CPT-11, 5-FU and l-LV
CPT-11, 5-FU and l-LV is a Topoisomerase inhibitor Small molecule drug developed by Taiho Pharmaceutical Co., Ltd.. It is currently in Phase 2 development for Colorectal cancer, Breast cancer.
Topoisomerase I inhibitor
Topoisomerase I inhibitor Used for Colorectal cancer, Breast cancer.
At a glance
| Generic name | CPT-11, 5-FU and l-LV |
|---|---|
| Sponsor | Taiho Pharmaceutical Co., Ltd. |
| Drug class | Topoisomerase inhibitor |
| Target | Topoisomerase I |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CPT-11 (irinotecan) works by inhibiting topoisomerase I, an enzyme involved in DNA replication and transcription. This leads to DNA damage and ultimately cell death in rapidly dividing cancer cells.
Approved indications
- Colorectal cancer
- Breast cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
- Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer (PHASE2)
- FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. (PHASE3)
- Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM (PHASE2)
- CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (PHASE1)
- Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer (PHASE2)
- Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer (NA)
- Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer (PHASE2)
- Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CPT-11, 5-FU and l-LV CI brief — competitive landscape report
- CPT-11, 5-FU and l-LV updates RSS · CI watch RSS
- Taiho Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about CPT-11, 5-FU and l-LV
What is CPT-11, 5-FU and l-LV?
How does CPT-11, 5-FU and l-LV work?
What is CPT-11, 5-FU and l-LV used for?
Who makes CPT-11, 5-FU and l-LV?
What drug class is CPT-11, 5-FU and l-LV in?
What development phase is CPT-11, 5-FU and l-LV in?
What are the side effects of CPT-11, 5-FU and l-LV?
What does CPT-11, 5-FU and l-LV target?
Related
- Drug class: All Topoisomerase inhibitor drugs
- Target: All drugs targeting Topoisomerase I
- Manufacturer: Taiho Pharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Colorectal cancer
- Indication: Drugs for Breast cancer
- Compare: CPT-11, 5-FU and l-LV vs similar drugs
- Pricing: CPT-11, 5-FU and l-LV cost, discount & access